CRLconf 0.70

reproxalap — CRL

$ALDX · Aldeyra Therapeutics, Inc. · dry eye disease

Event date

Date TBD

Sponsor runway

38 mo

$65.0M liquid

Evidence

“it may issue a Complete Response Letter and require that Aldeyra conduct additional clinical trials and submit the results of those clinical trials before the application will be reconsidered.”

Source: 8-K filed 2023-10-16View on EDGAR ↗0001193125-23-256532

Comparable historical crls· last 5 years · same event type

No comparable historical outcomes in our database yet — backfill of past readouts arrives next ingestion cycle.

Recent insider activity· ±90 days

No insider Form 4 activity reported on $ALDX in the 90 days around this event.

← All catalysts for $ALDX